Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.

Hall KC, Bernier SG, Jacobson S, Liu G, Zhang PY, Sarno R, Catanzano V, Currie MG, Masferrer JL.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):11057-11062. doi: 10.1073/pnas.1821045116. Epub 2019 May 13.

2.

Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.

Ferrero VT, Oset MM, Masferrer JP, Pardo EH, Sorolla EJ, Largo SC; PrevaDIOR Study Group.

Clin Transl Oncol. 2019 Apr 5. doi: 10.1007/s12094-019-02102-1. [Epub ahead of print]

PMID:
30949931
3.

Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.

Buys ES, Zimmer DP, Chickering J, Graul R, Chien YT, Profy A, Hadcock JR, Masferrer JL, Milne GT.

Nitric Oxide. 2018 Aug 1;78:72-80. doi: 10.1016/j.niox.2018.05.009. Epub 2018 May 31. Review.

4.

Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.

Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, Long K, Miyashiro J, Ranganath S, Jacobson S, Tang K, Im GJ, Sheppeck J 2nd, Moore JD, Sykes K, Wakefield J, Sarno R, Banijamali AR, Profy AT, Milne GT, Currie MG, Masferrer JL.

J Pharmacol Exp Ther. 2018 Jun;365(3):664-675. doi: 10.1124/jpet.117.247429. Epub 2018 Apr 11.

PMID:
29643251
5.

The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.

Flores-Costa R, Alcaraz-Quiles J, Titos E, López-Vicario C, Casulleras M, Duran-Güell M, Rius B, Diaz A, Hall K, Shea C, Sarno R, Currie M, Masferrer JL, Clària J.

Br J Pharmacol. 2018 Mar;175(6):953-967. doi: 10.1111/bph.14137. Epub 2018 Jan 31.

6.

The Soluble Guanylate Cyclase Stimulator IWP-953 Increases Conventional Outflow Facility in Mouse Eyes.

Ge P, Navarro ID, Kessler MM, Bernier SG, Perl NR, Sarno R, Masferrer J, Hannig G, Stamer WD.

Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1317-26. doi: 10.1167/iovs.15-18958.

7.

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.

Ranganath S, Bhandari A, Avitahl-Curtis N, McMahon J, Wachtel D, Zhang J, Leitheiser C, Bernier SG, Liu G, Tran TT, Celino H, Tobin J, Jung J, Zhao H, Glen KE, Graul C, Griffin A, Schairer WC, Higgins C, Reza TL, Mowe E, Rivers S, Scott S, Monreal A, Shea C, Bourne G, Coons C, Smith A, Tang K, Mandyam RA, Masferrer J, Liu D, Patel DV, Fretzen A, Murphy CA, Milne GT, Smythe ML, Carlson KE.

PLoS One. 2015 Nov 10;10(11):e0141330. doi: 10.1371/journal.pone.0141330. eCollection 2015.

8.

Renal effects induced by prolonged mPGES1 inhibition.

Salazar F, Vazquez ML, Masferrer JL, Mbalaviele G, Llinas MT, Saez F, Arhancet G, Salazar FJ.

Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F68-74. doi: 10.1152/ajprenal.00492.2013. Epub 2013 Nov 6.

9.

Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC-MS/MS.

Palandra J, Finelli A, Zhu M, Masferrer J, Neubert H.

Anal Chem. 2013 Jun 4;85(11):5522-9. doi: 10.1021/ac4006765. Epub 2013 May 16.

PMID:
23638938
10.

pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood.

Zhu M, Pleasic-Williams S, Lin TH, Wunderlich DA, Cheng JB, Masferrer JL.

J Transl Med. 2013 Mar 14;11:65. doi: 10.1186/1479-5876-11-65.

11.

Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low.

Salazar F, Salazar FJ, Saez F, Reverte V, Zweifel B, Dufield D, Radabaugh M, Graneto M, Llinas MT, Masferrer JL.

J Cardiovasc Pharmacol. 2013 Apr;61(4):329-36. doi: 10.1097/FJC.0b013e31828399ae.

PMID:
23288201
12.

Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis.

Staten NR, Welsh EA, Sidik K, McDonald SA, Dufield DR, Maqsodi B, Ma Y, McMaster GK, Mathews RW, Arch RH, Masferrer JL, Souberbielle BE.

Fibrogenesis Tissue Repair. 2012 Dec 27;5(1):21. doi: 10.1186/1755-1536-5-21.

13.

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.

Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):1114-9. doi: 10.1016/j.bmcl.2012.11.109. Epub 2012 Dec 6.

PMID:
23260349
14.

Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model.

Radi ZA, Heuvelman DM, Masferrer JL, Benson EL.

Dig Dis Sci. 2011 Aug;56(8):2283-91. doi: 10.1007/s10620-011-1628-8. Epub 2011 Mar 5.

PMID:
21374065
15.

High-throughput screening assay for sphingosine kinase inhibitors in whole blood using RapidFire® mass spectrometry.

Highkin MK, Yates MP, Nemirovskiy OV, Lamarr WA, Munie GE, Rains JW, Masferrer JL, Nagiec MM.

J Biomol Screen. 2011 Feb;16(2):272-7. doi: 10.1177/1087057110391656.

PMID:
21297110
16.

Anti-PDGF-B monoclonal antibody reduces liver fibrosis development.

Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, Moffat MA, Katragadda M, Violand BN, Arch RH, Masferrer JL.

Hepatol Res. 2010 Nov;40(11):1128-41. doi: 10.1111/j.1872-034X.2010.00718.x. Epub 2010 Sep 28.

PMID:
20880061
17.

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: the three microdose candidates.

Wang JL, Aston K, Limburg D, Ludwig C, Hallinan AE, Koszyk F, Hamper B, Brown D, Graneto M, Talley J, Maziasz T, Masferrer J, Carter J.

Bioorg Med Chem Lett. 2010 Dec 1;20(23):7164-8. doi: 10.1016/j.bmcl.2010.07.059. Epub 2010 Jul 23.

PMID:
20728356
18.

Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.

Wang X, Heuvelman DM, Carroll JA, Dufield DR, Masferrer JL.

Cancer Invest. 2010 Jul;28(6):635-41. doi: 10.3109/07357901003630983.

PMID:
20394503
19.

A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.

Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, Ogawa S, Pegg L, Pelc M, Prinsen M, Schnute M, Wendling J, Wene S, Weinberg R, Wittwer A, Zweifel B, Masferrer J.

J Pharmacol Exp Ther. 2010 Jul;334(1):310-7. doi: 10.1124/jpet.110.165845. Epub 2010 Apr 14.

PMID:
20392816
20.

Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.

Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, Graneto M.

J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. doi: 10.1124/jpet.110.166967. Epub 2010 Apr 8.

PMID:
20378715
21.

Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.

Rajagopalan LE, Davies MS, Kahn LE, Kornmeier CM, Shimada H, Steiner TA, Zweifel BS, Wendling JM, Payne MA, Loeffler RF, Case BL, Norton MB, Parikh MD, Nemirovskiy OV, Mourey RJ, Masferrer JL, Misko TP, Kolodziej SA.

J Pharmacol Exp Ther. 2010 Jun;333(3):707-16. doi: 10.1124/jpet.110.166033. Epub 2010 Mar 12.

PMID:
20228155
22.

Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.

Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL.

Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.

PMID:
20067770
23.

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.

Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):59-67. doi: 10.1016/j.ejphar.2009.06.058. Epub 2009 Jul 4.

PMID:
19580807
24.

Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.

Anderson GD, Keys KL, De Ciechi PA, Masferrer JL.

Inflamm Res. 2009 Feb;58(2):109-17. doi: 10.1007/s00011-009-8149-3.

PMID:
19184362
25.

Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.

López-Parra M, Titos E, Horrillo R, Ferré N, González-Périz A, Martínez-Clemente M, Planagumà A, Masferrer J, Arroyo V, Clària J.

J Lipid Res. 2008 Dec;49(12):2513-23. doi: 10.1194/jlr.M800101-JLR200. Epub 2008 Jul 21.

26.

Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.

Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.

Eur J Pharmacol. 2008 Jun 24;588(1):93-8. doi: 10.1016/j.ejphar.2008.03.057. Epub 2008 Apr 6.

PMID:
18457826
27.

A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.

Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, Masferrer JL.

Eur J Pharmacol. 2008 Apr 14;584(1):166-74. doi: 10.1016/j.ejphar.2008.01.021. Epub 2008 Feb 5.

PMID:
18295198
28.

Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.

Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Clària J.

J Pharmacol Exp Ther. 2007 Dec;323(3):778-86. Epub 2007 Aug 31.

PMID:
17766677
29.

Development of a fluorescence-based enzyme assay of human 5-lipoxygenase.

Pufahl RA, Kasten TP, Hills R, Gierse JK, Reitz BA, Weinberg RA, Masferrer JL.

Anal Biochem. 2007 May 15;364(2):204-12. Epub 2007 Feb 14.

PMID:
17376394
30.

The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

Planagumà A, Clària J, Miquel R, López-Parra M, Titos E, Masferrer JL, Arroyo V, Rodés J.

FASEB J. 2005 Jul;19(9):1120-2. Epub 2005 May 4.

PMID:
15876570
31.

The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.

López-Parra M, Clària J, Titos E, Planagumà A, Párrizas M, Masferrer JL, Jiménez W, Arroyo V, Rivera F, Rodés J.

J Hepatol. 2005 Jan;42(1):75-81.

PMID:
15629510
32.

Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling.

Paccani SR, Patrussi L, Ulivieri C, Masferrer JL, D'Elios MM, Baldari CT.

Blood. 2005 Mar 1;105(5):2042-8. Epub 2004 Oct 28.

33.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

PMID:
15494548
34.

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL.

Cancer Res. 2004 Jan 1;64(1):279-85.

35.

Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.

Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL.

J Pharmacol Exp Ther. 2004 Mar;308(3):929-34. Epub 2004 Jan 7.

PMID:
14711936
36.

The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91.

37.

Cyclooxygenase-2 inhibitors in cancer prevention and treatment.

Masferrer JL.

Adv Exp Med Biol. 2003;532:209-13. Review. No abstract available.

PMID:
12908559
38.

COX-2 inhibitors as radiosensitizing agents for cancer therapy.

Davis TW, Hunter N, Trifan OC, Milas L, Masferrer JL.

Am J Clin Oncol. 2003 Aug;26(4):S58-61. Review.

PMID:
12902857
39.

Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.

Milas L, Mason KA, Crane CH, Liao Z, Masferrer J.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):15-24. Review.

PMID:
12800601
40.
41.

Renal effects of selective cyclooxygenase inhibition in experimental liver disease.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Arroyo V, Rivera F, Rodés J.

Adv Exp Med Biol. 2003;525:133-6. No abstract available.

PMID:
12751752
42.

Cyclooxygenase-2 in human pathological disease.

Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, Masferrer JL.

Adv Exp Med Biol. 2002;507:177-84. Review.

PMID:
12664583
43.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.

Cancer Res. 2002 Nov 15;62(22):6706-11.

44.

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL.

Cancer Res. 2002 Oct 15;62(20):5778-84.

45.

Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ.

Cancer Res. 2002 Oct 1;62(19):5405-7.

46.

Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.

Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, Soslow RA, Masferrer JL.

Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):13-8. Review.

PMID:
12051953
47.

Celecoxib: a specific COX-2 inhibitor with anticancer properties.

Koki AT, Masferrer JL.

Cancer Control. 2002 Mar-Apr;9(2 Suppl):28-35. Review.

PMID:
11965228
48.

Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Altuna R, Arroyo V, Rivera F, Rodés J.

Br J Pharmacol. 2002 Feb;135(4):891-900.

49.

Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.

Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE.

Anticancer Res. 2001 Sep-Oct;21(5):3425-32.

PMID:
11848504
50.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.

Cancer Res. 2002 Feb 1;62(3):625-31.

Supplemental Content

Loading ...
Support Center